Recent news on Procrit

CHMP backs Roche's Mircera  -  25 May 2007
Pharma Times (subscription),A second panel is expected to meet in the next few months to review ESAs (but not Procrit) for patients with kidney disease.

EU watchdog clears Roche's anaemia drug Mircera  -  25 May 2007
San Diego Union Tribune,The US Food and Drug Administration is reviewing the class of drugs, which includes Amgen Inc.'s Aranesp and Epogen and Johnson & Johnson's Procrit,

Biologic Mircera Approved in Europe for Treating Anemia in Kidney ...  -  25 May 2007
Biologic Drug Report,Mircera is a synthetic erythropoiesis-stimulating agent (ESA) which will compete with Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit.

FDA issues approvable letter for Roche's Mircera  -  May 21, 2007
Pharma Times (subscription),A second panel is expected to meet in the next few months to review ESAs (but not Procrit) for patients with kidney disease and Mr Abercrombie said that "we

Sales Agent Makes Allegations About Improper Anemia Drug Marketing ...  -  May 14, 2007
Medical News Today (press release),One memo calculated that under the program, a physician who purchased nearly $1 million of Procrit over 15 months would receive a check for $237885,

Look behind the headlines of pharmaceutical industry  -  May 18, 2007
Seattle Times,...drug Procrit, jointly produced by Amgen. Medicare has halted coverage for Procrit for cancer due to safety concerns. Johnson & Johnson declined to comment.

FDA Panel Wants More Anemia Drug Studies  -  May 14, 2007
First Coast News,..."When used according to the label, Procrit is safe and effective, and has an acceptable risk-benefit profile," said J&J's Stephanie Fagan.

Health Highlights: May 16, 2007  -  May 16, 2007
Atlanta Journal Constitution (subscription),US Medicare officials have proposed sharp cuts in reimbursements for the anemia drugs Aranesp and Procrit following recent reports that the drugs -- widely

Safety concerns over EPO likely to hit pharma firms  -  May 16, 2007
Financial Express,Aranesp and Epogen had combined sales of $6.6 billion while J&J's Procrit has sales of $3.2 billion. According to Kiran Mazumdar Shaw, chairman & managing

FDA panel wants more anemia drug studies  -  May 13, 2007
Jordan Falls News,..."When used according to the label, Procrit is safe and effective, and has an acceptable risk-benefit profile," said J&J‘s Stephanie Fagan.

Federal panel wants new limits, more safety studies on Amgen and ...  -  May 10, 2007
International Herald Tribune,Aranesp and Procrit are man-made versions of a naturally occurring protein that increases production of red blood cells. The drugs are approved to treat the

Corruption is a sign of a selfish culture  -  May 18, 2007
Winston-Salem Journal (subscription),...dollars to doctors every year in return for giving the patients anemia medicines (Aranesp, Epogen, and Procrit), which regulators now say may be unsafe.

Shares of Anemia Drug Makers Slide as Medicare Threatens to Cut ...  -  May 15, 2007
New York Times,The proposals, which would also apply to Johnson & Johnson’s anemia drug, Procrit, follow recent reports suggesting that the drugs, widely used to treat

More Misery for Amgen  -  May 15, 2007
BusinessWeekMedicare's rules would also affect Procrit, a similar drug made by Johnson & Johnson (JNJ). Bank of America analyst William Q. Sargent, Jr. called the

Amgen slumps on proposed Medicare coverage cuts  -  May 15, 2007
MarketWatch...is affected as well; after licensing rights to Epogen from Amgen in the 1980s, the company has since sold it under the brand name Procrit.

New anaemia med warnings  -  May 12, 2007
Health24.com,The drugs include darbepoetin (Aranesp) and epoetin alfa (Epogen and Procrit). They are genetically engineered versions of a natural protein, erythropoietin

Ahead of the Bell: Johnson & Johnson  -  May 15, 2007
Forbes,Goldman Sachs analyst Lawrence Keusch said he expected the changes, and estimates Procrit sales will decrease 10 percent in 2007.

Advisers urge restrictions on anemia drugs  -  May 12, 2007
Inland Valley Daily Bulletin,The drugs - Aranesp from Amgen and Procrit from Johnson & Johnson - are used by about a half-million American cancer patients a year and have billions of

FDA vote sends Amgen investors for exits  -  May 11, 2007
Washington Post,The medicines -- Amgen's Aranesp and Epogen and J&J's Procrit -- had already been under considerable pressure as a raft of negative clinical news led to

FDA Panel Questions Safety of Anemia Drug  -  May 10, 2007
Washington Post,At the same time, a high FDA official said his office will look into how another section of the agency approved advertisements suggesting that Procrit,

Stronger warning is sought on drugs  -  May 11, 2007
Ventura County Star (subscription),Lilla Romeo, a breast cancer patient who has taken Aranesp and Procrit, told the panel that she was assured when she began her treatment that the drugs were

The Danger in Drug Kickbacks  -  May 13, 2007
New York Times,As Alex Berenson and Andrew Pollack laid bare in The Times on May 9, wide use of the medicines — Aranesp and Epogen, from Amgen; and Procrit, from Johnson

The danger in drug kickbacks  -  May 17, 2007
International Herald Tribune,As Alex Berenson and Andrew Pollack laid bare in The New York Times last week, wide use of the medicines - Aranesp and Epogen, from Amgen; and Procrit,

For-Profit Dialysis Centers Overuse Anemia Drug  -  May 4, 2007
Lawyers and Settlements,Epogen, Procrit, and Aranesp are all erythropoiesis-stimulating agents (ESAs) that work by stimulating the bone marrow to make more red blood cells,

Although many evolving and offer limited subtypes.  -  26 Apr 2007
Journal lycéen,Store constituted this study damage and study by Procrit advocated. The objective is probably hospital and cancer. Limit physicians change in tell you

Data about Procrit  -  Apr 9, 2007
Citrus County Chronicle,All three doctors in our office went through similar conversations several times since news about Procrit and Aranesp were featured in the media.

Pinegar sentenced to 33 months in prison  -  Apr 22, 2007
Alva Review Courier,Through his plea, Pinegar has admitted that he intentionally submitted false claims to Medicare for two prescription medications: Procrit and Remicade.

Ortho Biotech Revises Prescribing Information for PROCRIT(R ...  -  Apr 3, 2007
Drug Newswire (press release),The Company has worked closely with the FDA to ensure that the PROCRIT label provides physicians and patients with the information they need to make the

US biotech company Amgen reports slowing sales growth in Q1 2007 ...  -  Apr 23, 2007
FinFacts Ireland,The FDA action also related to to Johnson & Johnson's Procrit anaemia drug. The studies signalled serious safety risks involved using the drugs in ways not

Amgen and J&J Funnel Tax Dollars Through Kidney and Cancer Patients  -  Apr 17, 2007
Lawyers and Settlements,Amgen manufactures and markets darbepoetin as Aranesp, and epoetin is sold under the names Procrit and Epogen. But Procrit is distributed by Ortho Biotech

J&J profits higher despite lower stent sales  -  Apr 17, 2007
MSNBCThe turnaround for Procrit combined with strong sales across J&J's diversified business – including gains in consumer products and orthopaedic implants – to

Former Alva doctor sentenced to prison for Medicare fraud  -  Apr 20, 2007
KTEN,Procrit is used to treat anemia and Remicade is used to treat Crohn's disease and rheumatoid arthritis. Prosecutors say Pinegar billed Medicare for more

Lawmakers Go After Amgen and J&J Over Off-Label Sales of Anemia Drugs  -  Apr 22, 2007
Lawyers and Settlements,The drugs at issue include Aranesp, the brand name for darbepoetin, and Epogen and Procrit, the brand names for epoetin. Amgen manufactures all three drugs,

Amgen shares gain on Aranesp study results  -  Apr 19, 2007
MarketWatchThe FDA then said that the warning labels on Aranesp, Epogen, and Procrit would be strengthened to the most severe level to highlight severe side effects,

Amgen Says Aranesp's Death Risk No Higher in Chemo (Update5)  -  Apr 19, 2007
BloombergAmgen's Aranesp and an older version, Epogen, and similar anemia medications, including Johnson & Johnson's Procrit, have come under scrutiny from lawmakers

Dosing For Dollars  -  Apr 17, 2007
Forbes,This led the US Food and Drug Administration to put its strongest black-box warning on Epogen and two similar drugs, Aranesp and Procrit, in early March.

J&J Net Income Falls 22 Percent After Acquisitions (Update5)  -  Apr 17, 2007
BloombergSales of Procrit, an anemia drug re-labeled in March to warn of risks of heart attacks and strokes, rose less than one percent, to $530 million.

Under The Weather At J&J  -  Apr 17, 2007
BusinessWeekSafety concerns have dampened demand for coronary stents and the anemia drug Procrit. Meanwhile, J&J's new schizophrenia drug--one it's counting on to

J&J Profit Falls 22 Percent After Acquisitions (Update1)  -  Apr 17, 2007
BloombergJ&J was forced by US regulators in March to warn patients that its anemia drug Procrit, which generated $3.2 billion last year, raised risks of death,

Johnson & Johnson Beats Forecasts, Shares Up 3%  -  Apr 17, 2007
Seeking Alpha,However, the company was forced in March to warn patients that its anemia drug Procrit ($3.2 billion in 2006 sales) raised risks of death, heart attack and

J&J profits higher despite lower stent sales  -  Apr 17, 2007
Financial Times (subscription),...tiny mesh tubes used to prop open coronary arteries, and anti-anaemia treatments Procrit/Eprex - are facing significant safety questions.

Oncologists Reduce Use of Amgen's Aranesp: Survey  -  Apr 3, 2007
Cancerpage.com,Aranesp, along with Johnson & Johnson's drug Procrit, is already approved to treat chemotherapy-induced anemia, an indication that accounted for about 45%

Oncologists Reduce Use of Amgen's Aranesp -Survey  -  Apr 1, 2007
Reuters.uk,N: Quote, Profile , Research) drug Procrit, is already approved to treat chemotherapy-induced anemia, an indication that accounted for about 45 percent of

Kidney-Disease Group Advises  -  Apr 12, 2007
Wall Street Journal (subscription),The drugs, which are known as erythropoiesis-stimulating agents, or ESA's, include Amgen's Aranesp and Epogen and J&J's Procrit.

Oncologists reduce use of Amgen's Aranesp: survey  -  Mar 30, 2007
Scientific AmericanAranesp, along with Johnson & Johnson's drug Procrit, is already approved to treat chemotherapy-induced anemia, an indication that accounted for about 45

Aranesp linked to higher death rate in cancer trial  -  Apr 17, 2007
Pharma Times (subscription),...safety and dosage information should be added the labels of Amgen's Aranesp and Epogen (epoetin alfa) and Johnson & Johnson's Procrit (epoetin alfa).

Amgen delays results release to include study data  -  Apr 11, 2007
MarketWatch...which has since marketed the drug under the name Procrit. The drugs, known as erythropoiesis-stimulating agents, or ESAs, are used to boost the number of

Analysts, investors aloof about J&J stock  -  Apr 2, 2007
Newark Star Ledger,Johnson & Johnson is under pressure on three main franchises: drug-coated stents; its anemia treatment, Procrit: and its lineup of antipsychotic drugs.

Facing Reality on Follow-On Biologics  -  Apr 23, 2007
American Enterprise Institute,It had nothing to say about biologics like Epogen, Procrit, and Aranesp for anemia; Enbrel and Remicade for rheumatoid arthritis; and Avastin and Herceptin

LegalView.com Launches FDA Drug Database  -  Apr 14, 2007
PR Web (press release),...as Zelnorm, Procrit and Pergolide, and informative articles and blogs on medical devices like the Composix hernia mesh patch and Guidant defibrillators.

Kidney guidelines could hurt anemia drug sales  -  Apr 13, 2007
Los Angeles Times,The change could hurt sales of Amgen Inc.'s key anemia drugs, Aranesp and Epogen, which brought in $6.6 billion in 2006, and Johnson & Johnson's Procrit,

Kidney Foundation lowers target hemoglobin range  -  Apr 12, 2007
Scientific AmericanThe changes could hurt sales of Amgen Inc.'s key anemia drugs Aranesp and Epogen, which brought in $6.6 billion in 2006, and Johnson & Johnson's Procrit,

Affymax cites positive Hematide data  -  Apr 12, 2007
BusinessWeekAmgen Inc. and Johnson & Johnson both sell Epoetin Alfa drugs, called Epogen and Procrit, respectively. Affymax's newly released data deals with 90 patients

Important Drug Warnings Issued  -  Mar 28, 2007
24-7PressRelease.com (press release).../24-7PressRelease/ - March 28, 2007 - The FDA recently added black box warnings to the $10 billion a year anemia drugs Procrit, Epogen and Aransep,

Red and White Results at Amgen  -  Apr 24, 2007
Motley FoolThe market is even larger, as Johnson & Johnson (NYSE: JNJ) sells Procrit, a near-identical compound to Epogen. The next best-selling drug, Enbrel,

Ahead of the Bell: Johnson & Johnson  -  Mar 30, 2007
Houston Chronicle,Sales of anemia drug Procrit should drop after a new Food and Drug Administration warning and new Medicare reimbursement policies, she said.

The big 'if'  -  Mar 31, 2007
Therapeutics Daily (subscription) (press release),The first blow came when studies showed that EPO products ? the red-blood cell booster erythropoetin marketed as Epogen and Aranesp by Amgen and as Procrit

Erythropoietin drugs: What to know about anemia-fighting medications  -  Mar 29, 2007
MayoClinic.comIncluded in the warning are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen, Procrit). Here to answer some questions about erythropoietin and ESAs is

Analysis: J&J Q1 clouded on stent worries  -  Apr 17, 2007
United Press International..."We note that investors will be paying particular attention to this update, given the recent concerns over Procrit, the relatively slow launch of Invega and

Health Highlights: April 22, 2007  -  Apr 22, 2007
Atlanta Journal Constitution (subscription),Last month, the House Committee on Energy and Commerce sent letters to drug makers Amgen (Epogen and Aranesp) and Johnson & Johnson (Procrit),

Johnson & Johnson Reports 2007 First-Quarter Results: Sales ...  -  Apr 17, 2007
PR Newswire (press release),Intl 187 215 -13% -18% 5% WW 303 325 -7% -10% 3% EPREX/PROCRIT US 530 527 1% 1% -- Intl 287 259 11% 4% 7% WW 817 786 4% 2% 2% Hormonal Contraceptives US

Anemia drug trial's tardiness at issue  -  Apr 20, 2007
Los Angeles Times,Meanwhile, sales of the drugs, classified under the name erythropoietin and also sold by Johnson & Johnson under the brand name Procrit, have grown

Study Supports Use of Anemia Drug From Amgen  -  Apr 19, 2007
New York Times,...in light of studies indicating that Aranesp and similar anemia drugs like Amgen’s Epogen and Johnson & Johnson’s Procrit were causing blood clots,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional